Leukemia · 2020
Complex landscape of alternative splicing in myeloid neoplasms.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hershberger Courtney E, Moyer Devlin C, Adema Vera, Kerr Cassandra M, Walter Wencke, Hutter Stephan, Meggendorfer Manja, Baer Constance, Kern Wolfgang, Nadarajah Niroshan, Twardziok Sven, Sekeres Mikkael A, Haferlach Claudia, Haferlach Torsten, Maciejewski Jaroslaw P, Padgett Richard A
Аннотация
Myeloid neoplasms are characterized by frequent mutations in at least seven components of the spliceosome that have distinct roles in the process of pre-mRNA splicing. Hotspot mutations in SF3B1, SRSF2, U2AF1 and loss of function mutations in ZRSR2 have revealed widely different aberrant splicing signatures with little overlap. However, previous studies lacked the power necessary to identify commonly mis-spliced transcripts in heterogeneous patient cohorts. By performing RNA-Seq on bone marrow samples from 1258 myeloid neoplasm patients and 63 healthy bone marrow donors, we identified transcripts frequently mis-spliced by mutated splicing factors (SF), rare SF mutations with common alternative splicing (AS) signatures, and SF-dependent neojunctions. We characterized 17,300 dysregulated AS events using a pipeline designed to predict the impact of mis-splicing on protein function. Meta-splicing analysis revealed a pattern of reduced levels of retained introns among disease samples that was exacerbated in patients with splicing factor mutations. These introns share characteristics with "detained introns," a class of introns that have been shown to promote differentiation by detaining pro-proliferative transcripts in the nucleus. In this study, we have functionally characterized 17,300 targets of mis-splicing by the SF mutations, identifying a common pathway by which AS may promote maintenance of a proliferative state.
Предметные рубрики MeSH
Alternative SplicingBiomarkers, TumorBone MarrowBone Marrow CellsCase-Control StudiesChromosome DeletionCluster AnalysisDisease SusceptibilityGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLoss of Function MutationMutationMyelodysplastic SyndromesMyeloproliferative DisordersRNA Splicing FactorsTranscriptome